86MO Anti-HHV-8 immunity defines dostarlimab efficacy in HIV-associated Kaposi’s sarcoma: Results of the STARKAP trial

ESMO rare cancers. 2026 Open access

Read full text
Authors: Claudia Angela Maria Fulgenzi, Alessia Dalla Pria, A.G. Leone, E. Maher, E. Ferrer Martinez Del Perral, M.E. Flores, Catherine J. Reynolds, Daniel Martin Altmann, Rosemary Jane Boyton, Mark Bower, D.J. Pinato
DOI: 10.1016/j.esmorc.2026.100292
Cited by: 0

Abstract

Kaposi’s Sarcoma (KS) is a Human Herpesvirus-8 (HHV-8)-related malignancy more common in people living with HIV (PLWH). Programmed cell death-1 (PD-1) blockade shows promise. However, the role of HHV-8 immunity in tumour regression is unclear.

Fields of Study & Subjects

Viral-associated cancers and disorders Lymphoma Diagnosis and Treatment Herpesvirus Infections and Treatments

Publication details

Journal / source
ESMO rare cancers.
Volume
5
Pages
100292–100292
Publication date
1 March 2026
Language
EN